stockrowModerna, Inc.
MRNA Healthcare Biotechnology
Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024.
- Revenue
- +2.11%
- EPS
- +7.51%
- Free cash flow
- +38.9%
- Total debt
- +1,765.6%
Quarter to June 2026, against a year earlier
Follow MRNA
Alert me
Moderna, Inc. (MRNA) Current ratio
Moderna, Inc.'s current ratio at the end of the quarter to 30 June 2026 was 2.3×, down 1.0× from fiscal 2025 (3.3×). Over the past ten years it has ranged from 1.4× (fiscal 2020) to 7.9× (fiscal 2019); the current reading is higher than 40% of that period. That is below the Biotechnology industry median of 4.9× and below the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 3.3× | (10.30%) |
| FY2024 | 3.7× | 7.21% |
| FY2023 | 3.4× | 25.52% |
| FY2022 | 2.7× | 54.96% |
| FY2021 | 1.8× | 22.69% |
| FY2020 | 1.4× | (81.81%) |
| FY2019 | 7.9× | 12.43% |
| FY2018 | 7.0× | 71.49% |
| FY2017 | 4.1× | (38.74%) |
| FY2016 | 6.7× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 2.3× | (4.75%) |
| Mar 2026 | 2.4× | (26.85%) |
| Dec 2025 | 3.3× | (16.09%) |
| Sep 2025 | 3.9× | (0.02%) |
| 29 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| ROIV Roivant Sciences Ltd. compare | 16.7× |
| RVMD Revolution Medicines, Inc. compare | 8.4× |
| ARGX argenex SE compare | 5.1× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 3.6× |
| REGN Regeneron Pharmaceuticals, Inc. compare | 3.4× |
| GMAB Genmab A/S Sponsored ADR compare | 2.5× |
| VRTX Vertex Pharmaceuticals Incorporated compare | 2.3× |
| MRNA Moderna, Inc. | 2.3× |
| RPRX Royalty Pharma PLC compare | 1.3× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on MRNA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement